Skip to content

Study · Non-randomized trial · 2017

5 results

Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents.

Davies MJ, Leiter LA, Guerci B, Grunberger G, Ampudia-Blasco FJ, Yu C, Stager W, Niemoeller E, Souhami E, Rosenstock J

Diabetes, obesity & metabolism7 Jul 2017Cited by 26 (Europe PMC)

PMID28432746 (opens in a new tab)PMCIDPMC5697595 (opens in a new tab)DOI10.1111/dom.12980 (opens in a new tab)PepBankPUB-28432746
Read at sourcePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with type 2 diabetes, iGlarLixi reduced HbA1c more than insulin glargine in all baseline subpopulations at week 30.

    In plain wordsIn patients with diabetes, iGlarLixi reduced HbA1c more than insulin glargine across baseline subpopulations.

    Peptide
    Lixisenatide
    Outcome
    DecreaseHbA1c reduction at week 30
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In all subpopulations, iGlarLixi was consistently statistically superior to iGlar and Lixi alone in reducing HbA1c from baseline to week 30; higher proportions of patients achieved HbA1c <7% (<53 mmol/mol) with iGlarLixi vs iGlar and Lixi alone.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with type 2 diabetes, more iGlarLixi patients achieved HbA1c <7% than insulin glargine patients across baseline subpopulations.

    In plain wordsIn patients with diabetes, more iGlarLixi patients achieved the HbA1c target than insulin glargine patients.

    Peptide
    Lixisenatide
    Outcome
    IncreaseHbA1c target below 7%
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In all subpopulations, iGlarLixi was consistently statistically superior to iGlar and Lixi alone in reducing HbA1c from baseline to week 30; higher proportions of patients achieved HbA1c <7% (<53 mmol/mol) with iGlarLixi vs iGlar and Lixi alone.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with type 2 diabetes, iGlarLixi decreased 2-hour postprandial plasma glucose compared with insulin glargine.

    In plain wordsIn patients with diabetes, iGlarLixi decreased postmeal glucose compared with insulin glargine.

    Peptide
    Lixisenatide
    Outcome
    DecreasePostprandial plasma glucose
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Compared with iGlar, iGlarLixi resulted in a substantial decrease in 2-hour postprandial plasma glucose levels, and mitigation of weight gain, with no differences among subpopulations in incidence of symptomatic hypoglycaemia.
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with type 2 diabetes, iGlarLixi mitigated weight gain compared with insulin glargine.

    In plain wordsIn patients with diabetes, iGlarLixi limited weight gain compared with insulin glargine.

    Peptide
    Lixisenatide
    Outcome
    DecreaseWeight gain
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Compared with iGlar, iGlarLixi resulted in a substantial decrease in 2-hour postprandial plasma glucose levels, and mitigation of weight gain, with no differences among subpopulations in incidence of symptomatic hypoglycaemia.
  5. 05HumanNon-randomized trialSafety outcome

    In patients with type 2 diabetes, iGlarLixi did not increase hypoglycaemic risk compared with insulin glargine across baseline subpopulations.

    In plain wordsIn patients with diabetes, iGlarLixi did not increase hypoglycaemic risk compared with insulin glargine.

    Peptide
    Lixisenatide
    Outcome
    No significant changeHypoglycaemic risk
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    iGlarLixi consistently improved glycaemic control compared with iGlar and Lixi alone, without weight gain or increase in hypoglycaemic risk compared with iGlar in the subpopulations tested, regardless of baseline HbA1c, disease duration and BMI.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT02058147

Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM

Sanofin = 1,170Feb 2014 to Jun 2015

Type 2 Diabetes

Trial pageClinicalTrials.govUpdated 9 May 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.